skip-to-main

AUSTRALIAN PRODUCT INFORMATION - SPIKEVAX XBB.1.5 (ANDUSOMERAN) COVID-19 VACCINE

SPIKEVAX XBB.1.5 (andusomeran) COVID-19 Vaccine is indicated for:

Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.

Product Information

Consumer Medicine Information

AUSTRALIAN PRODUCT INFORMATION –
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (ELASOMERAN/DAVESOMERAN) COVID-19 VACCINE

SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 Vaccine is indicated for:

As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Product Information

Consumer Medicine Information

SPIKEVAX BIVALENT ORIGINAL/OMICRON (ELASOMERAN/IMELASOMERAN) COVID-19 VACCINE

SPIKEVAX BIVALENT ORIGINAL/OMICRON (elasomeran/imelasomeran) COVID-19 Vaccine has provisional approval for the indication below:

As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.

Product Information

Consumer Medicine Information

Spikevax (previously COVID‑19 Vaccine Moderna)

SPIKEVAX (elasomeran) COVID-19 Vaccine is indicated for:

Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 years of age and older.
 

SPIKEVAX (elasomeran) COVID-19 Vaccine has provisional approval for the indication below:

Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months of age to <6 years of age.

Product Information

Consumer Medicine Information

Tools

Report Adverse Events

Report any adverse events to Moderna via the Adverse Event Intake Portal or by calling 1800 344 018.

Contact Moderna

    © 2024 Moderna, Inc.

    AU-COV-2100002 10/2023